Erysipelothrix rhusiopathiae infectious disease

Summary

Erysipelothrix rhusiopathiae infectious disease (MONDO:0006752) is a disease. A subtype of Erysipelothrix infectious disease — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	Erysipelothrix rhusiopathiae infectious disease
Mondo ID	MONDO:0006752
EFO	EFO:1000928
MeSH	D004887
DOID	DOID:0050061
ICD-10-CM	A26
SNOMED CT	400105005
UMLS	C1276801
MedGen	266170
Is cancer (heuristic)	no

Also known as: erysipeloid · Erysipelothrix rhusiopathiae caused disease or disorder · Erysipelothrix rhusiopathiae disease or disorder

Disease family

This is a subtype of Erysipelothrix infectious disease. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious disease › bacterial infectious disease › gram-positive bacterial infections › Erysipelothrix infectious disease › Erysipelothrix rhusiopathiae infectious disease

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.